CTMX — CytomX Therapeutics, Inc.

Is CTMX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of August 19, 2026

CytomX Therapeutics, Inc. (CTMX) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $3.39. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

CytomX Therapeutics, Inc. (CTMX) is a small-cap clinical biotech with a differentiated Probody platform and multiple clinical-stage assets. The firm’s technology and prior partnerships create optionality for value‑accretive licensing or co-development deals, and sector dynamics (biologics demand and partner M&A activity) are supportive. However, the company faces typical biotech risks: binary trial outcomes, limited near-term cash runway, and potential dilution. Near-term sentiment is modestly constructive, but meaningful upside depends on positive clinical readouts or partnership milestones. Investors should balance platform upside and depressed valuation against high execution and financing risk when considering exposure.

Key factors

  • Probody platform differentiated approach to conditional activation of biologics with potential to improve therapeutic window and reduce off-target toxicity
  • Pipeline with multiple clinical-stage assets that can generate binary trial readouts and partnership interest (licensing or co-development optionality)
  • Partnerships and licensing history that can provide non-dilutive funding, milestone upside, and validation of platform
  • Valuation is relatively depressed versus peers, reflecting a risk-discounted biotech equity price that offers upside if clinical readouts are positive
  • Sector tailwinds for biologics, CDMO/CRO demand and heightened M&A/larger partner appetite for novel modalities
  • Short-term market tone is cautiously optimistic which could reduce near-term selling pressure, but biotech-specific volatility remains

Risks

  • High clinical and regulatory binary risk: negative or delayed trial data on lead programs would materially depress valuation
  • Limited cash runway and potential need for equity raises which would dilute existing shareholders
  • Dependency on partners for late‑stage development or commercialization; partner decisions or reprioritization can slow or terminate programs
  • Competitive risk from other immuno‑oncology modalities, bispecifics, ADCs and next‑gen biologics pursuing similar indications
  • Reimbursement and pricing pressure in oncology markets could limit future commercial upside
  • Macro-driven volatility and interest‑rate sensitivity that can disproportionately impact small-cap biotech stocks

See today's live rating, score and targets

Members see the live hourly rating for CTMX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.